MX2021001292A - Metodos para la modificacion genica de celulas hematopoyeticas. - Google Patents
Metodos para la modificacion genica de celulas hematopoyeticas.Info
- Publication number
- MX2021001292A MX2021001292A MX2021001292A MX2021001292A MX2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hematopoietic cells
- gene modification
- relates
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012239 gene modification Methods 0.000 title abstract 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 title abstract 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 2
- 208000016361 genetic disease Diseases 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 102000007327 Protamines Human genes 0.000 abstract 1
- 108010007568 Protamines Proteins 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229950008679 protamine sulfate Drugs 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712146P | 2018-07-30 | 2018-07-30 | |
| PCT/US2019/044237 WO2020028430A1 (en) | 2018-07-30 | 2019-07-30 | Methods for gene modification of hematopoietic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001292A true MX2021001292A (es) | 2021-07-15 |
Family
ID=69232048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001292A MX2021001292A (es) | 2018-07-30 | 2019-07-30 | Metodos para la modificacion genica de celulas hematopoyeticas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12685751B2 (enExample) |
| EP (1) | EP3830248A4 (enExample) |
| JP (2) | JP7664829B2 (enExample) |
| KR (1) | KR20210046004A (enExample) |
| CN (1) | CN112888777A (enExample) |
| AU (2) | AU2019315438B2 (enExample) |
| BR (1) | BR112021001757A2 (enExample) |
| CA (1) | CA3106241A1 (enExample) |
| IL (2) | IL280465B2 (enExample) |
| MX (1) | MX2021001292A (enExample) |
| SG (1) | SG11202100025QA (enExample) |
| WO (1) | WO2020028430A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102673203B1 (ko) | 2016-04-20 | 2024-06-10 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 |
| AU2018352583B2 (en) | 2017-10-16 | 2025-04-17 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency |
| US12539316B2 (en) | 2018-04-11 | 2026-02-03 | Spacecraft Seven, Llc | Compositions and methods for stem cell transplant |
| IL278213B2 (en) | 2018-04-27 | 2026-04-01 | Rocket Pharmaceuticals Ltd | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) |
| IL280465B2 (en) | 2018-07-30 | 2025-03-01 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Methods for gene modification of hematopoietic cells |
| BR112022021862A2 (pt) * | 2020-05-27 | 2023-02-28 | Univ Zuerich | Aperfeiçoadores de transdução inovadores e usos dos mesmos |
| WO2022032226A1 (en) | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| CN114763563B (zh) * | 2021-01-12 | 2024-04-30 | 深圳华大临床检验中心 | 一种提高慢病毒感染效率的方法 |
| AU2022264498A1 (en) | 2021-04-26 | 2023-09-28 | Strm.Bio Incorporated | Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia |
| AU2024381806A1 (en) * | 2023-11-14 | 2026-05-28 | The University Of North Carolina At Chapel Hill | Compositions and methods relating to antiviral therapeutics |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0377676B1 (en) | 1987-09-17 | 1995-05-24 | Massachusetts Institute Of Technology | Human erythroid-specific transcriptional enhancer |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| HK1050210B (en) | 1999-10-12 | 2007-08-24 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| GB0024550D0 (enExample) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| ATE446077T1 (de) | 2002-05-02 | 2009-11-15 | Univ Rochester | Vektoren mit beiden isoformen von beta- hexosaminidase |
| WO2004094642A2 (en) | 2003-04-24 | 2004-11-04 | Fondazione Centro San Raffaele Del Monte Tabor | Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof |
| JP2007054069A (ja) | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
| BE1016793A4 (fr) | 2005-10-04 | 2007-06-05 | Artelis | Procede de culture de cellules et dispositif permettant sa mise en oeuvre. |
| US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| WO2008136670A2 (en) | 2007-05-02 | 2008-11-13 | Erasmus University Medical Center Rotterdam | Improved methods and means for lentiviral gene delivery |
| AU2008262478B9 (en) | 2007-05-29 | 2014-06-19 | Aldevron, L.L.C. | Vectors and methods for genetic immunization |
| EP2520643B8 (en) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| DE102008063606A1 (de) | 2008-12-18 | 2010-06-24 | Eufets Ag | Ein-Vektor Tet-System und dessen Verwendung |
| WO2010126766A1 (en) | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| DE102009021592A1 (de) | 2009-05-15 | 2010-11-18 | Medizinische Hochschule Hannover | ASLV-Vektorsystem |
| EP2486137B1 (en) | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
| EP3868888A1 (en) | 2012-02-29 | 2021-08-25 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Retroviral transduction using poloxamers |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| US10280391B2 (en) | 2012-12-11 | 2019-05-07 | Pall Technology Uk Limited | Recipient for cell cultivation |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| US20160194660A1 (en) | 2012-12-21 | 2016-07-07 | Merck Sharp & Dohme Corp. | Expression vectors for recombinant protein production in mammalian cells |
| EP2792742A1 (en) | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
| GB201318347D0 (en) | 2013-10-16 | 2013-11-27 | Ucl Business Plc | Retroviral vectors |
| WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
| CA2947466A1 (en) | 2014-05-01 | 2015-11-05 | University Of Washington | In vivo gene engineering with adenoviral vectors |
| US11030531B2 (en) | 2014-06-06 | 2021-06-08 | Trustees Of Boston University | DNA recombinase circuits for logical control of gene expression |
| DK3194602T3 (da) * | 2014-09-18 | 2020-02-17 | Univ Montreal | Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler |
| GB201417042D0 (en) | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| MA41506A (fr) | 2015-02-13 | 2017-12-19 | Takeda Vaccines Inc | Procédés de production de virus pour produire des vaccins |
| MX2017011615A (es) | 2015-03-10 | 2018-04-11 | Univ Columbia | Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1. |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| EP3405215B1 (en) | 2016-01-19 | 2022-06-15 | The Regents of the University of California | Methods for the treatment of danon disease and other disorders of autophagy |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| KR20250134722A (ko) * | 2016-02-12 | 2025-09-11 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
| RS67367B1 (sr) | 2016-04-14 | 2025-11-28 | Ferring Ventures Ltd | Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom |
| KR102673203B1 (ko) | 2016-04-20 | 2024-06-10 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 |
| US20220323612A1 (en) * | 2016-06-13 | 2022-10-13 | Bluebird Bio, Inc. | Gene therapy of neuronal ceroid lipofuscinoses |
| US20190345450A1 (en) | 2016-06-17 | 2019-11-14 | Fred Hutchinson Cancer Research Center | Strategies to assess and/or produce cell populations with predictive engraftment potential |
| IL320371A (en) | 2016-09-08 | 2025-06-01 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Gene therapy for patients with fanconi anemia |
| MX2019006552A (es) * | 2016-12-06 | 2019-10-15 | Bluebird Bio Inc | Terapia génica para mucopolisacaridosis de tipo i. |
| CN110199028A (zh) * | 2016-12-06 | 2019-09-03 | 蓝鸟生物公司 | 用于ii型黏多糖贮积症的基因治疗 |
| US20180326022A1 (en) | 2017-04-21 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for improving heart function and treating heart failure |
| EP3615044A4 (en) | 2017-04-27 | 2021-01-20 | Fred Hutchinson Cancer Research Center | THERAPEUTIC FORMULAS CONTAINING CD34 + STEM CELLS DERIVED FROM NEGATIVE SELECTION |
| AU2018352583B2 (en) | 2017-10-16 | 2025-04-17 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency |
| US12539316B2 (en) | 2018-04-11 | 2026-02-03 | Spacecraft Seven, Llc | Compositions and methods for stem cell transplant |
| IL278213B2 (en) | 2018-04-27 | 2026-04-01 | Rocket Pharmaceuticals Ltd | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) |
| EP3820537A4 (en) | 2018-07-12 | 2022-04-13 | Spacecraft Seven, LLC | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE |
| IL280465B2 (en) | 2018-07-30 | 2025-03-01 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Methods for gene modification of hematopoietic cells |
| JP2021533831A (ja) | 2018-08-16 | 2021-12-09 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | ウイルスベクターのための生成方法 |
| US20220143215A1 (en) | 2019-02-12 | 2022-05-12 | Spacecraft Seven, Llc | Gene therapy vectors for treatment of danon disease |
| KR20220012266A (ko) | 2019-05-23 | 2022-02-03 | 스페이스크래프트 세븐, 엘엘씨 | 영아 악성 골화석증을 위한 유전자 요법 벡터 |
| CA3177341A1 (en) | 2020-05-20 | 2021-11-25 | Chester Bittencort SACRAMENTO | Engineered parkin and uses thereof |
| WO2022017630A1 (en) | 2020-07-23 | 2022-01-27 | Ucl Business Ltd | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
| AU2021321412A1 (en) | 2020-08-05 | 2023-04-06 | Spacecraft Seven, Llc | Adeno-associated viral vector for GLUT1 expression and uses thereof |
| IL300187A (en) | 2020-08-05 | 2023-03-01 | Spacecraft Seven Llc | Gene therapy CSRP3 (protein 3 rich in cysteine and glycine) |
| WO2022032226A1 (en) | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| CN116887868A (zh) | 2020-12-07 | 2023-10-13 | 太空飞船七有限责任公司 | 达农病的治疗 |
| CA3240080A1 (en) | 2021-12-08 | 2023-06-15 | Christopher Dean HERZOG | Junctophilin-2 (jph2) gene therapy using aav vector |
| CA3240616A1 (en) | 2021-12-10 | 2023-06-15 | Christopher Dean HERZOG | Troponin c (tnnc1) gene therapy using aav vector |
| MX2024009685A (es) | 2022-02-08 | 2024-08-19 | Spacecraft Seven Llc | Vector viral adenoasociado para la expresion de glut1 y usos del mismo. |
| JP2025512574A (ja) | 2022-04-22 | 2025-04-17 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | ＡＡＶベクターを使用するＢ細胞リンパ腫２関連Ａｎｔｈａｎｏｇｅｎｅ ３ （ＢＡＧ３）遺伝子治療 |
-
2019
- 2019-07-30 IL IL280465A patent/IL280465B2/en unknown
- 2019-07-30 AU AU2019315438A patent/AU2019315438B2/en active Active
- 2019-07-30 JP JP2021505315A patent/JP7664829B2/ja active Active
- 2019-07-30 BR BR112021001757-7A patent/BR112021001757A2/pt unknown
- 2019-07-30 EP EP19844952.2A patent/EP3830248A4/en active Pending
- 2019-07-30 WO PCT/US2019/044237 patent/WO2020028430A1/en not_active Ceased
- 2019-07-30 MX MX2021001292A patent/MX2021001292A/es unknown
- 2019-07-30 CA CA3106241A patent/CA3106241A1/en active Pending
- 2019-07-30 SG SG11202100025QA patent/SG11202100025QA/en unknown
- 2019-07-30 CN CN201980049019.6A patent/CN112888777A/zh active Pending
- 2019-07-30 KR KR1020217005904A patent/KR20210046004A/ko active Pending
- 2019-07-30 US US17/264,275 patent/US12685751B2/en active Active
- 2019-07-30 IL IL316185A patent/IL316185A/en unknown
-
2024
- 2024-12-13 JP JP2024218336A patent/JP2025038075A/ja active Pending
-
2026
- 2026-04-30 AU AU2026203310A patent/AU2026203310A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020028430A1 (en) | 2020-02-06 |
| BR112021001757A2 (pt) | 2021-05-11 |
| AU2019315438A1 (en) | 2021-01-28 |
| US20210290685A1 (en) | 2021-09-23 |
| IL280465B2 (en) | 2025-03-01 |
| CA3106241A1 (en) | 2020-02-06 |
| JP7664829B2 (ja) | 2025-04-18 |
| JP2025038075A (ja) | 2025-03-18 |
| KR20210046004A (ko) | 2021-04-27 |
| AU2026203310A1 (en) | 2026-06-25 |
| IL316185A (en) | 2024-12-01 |
| AU2019315438B2 (en) | 2026-02-05 |
| US12685751B2 (en) | 2026-07-21 |
| IL280465A (en) | 2021-03-25 |
| JP2021532776A (ja) | 2021-12-02 |
| EP3830248A4 (en) | 2022-05-04 |
| SG11202100025QA (en) | 2021-01-28 |
| CN112888777A (zh) | 2021-06-01 |
| EP3830248A1 (en) | 2021-06-09 |
| IL280465B1 (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502046A1 (en) | Aav vectors for retinal and cns gene therapy | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| WO2022032154A3 (en) | Compositions for the delivery of payload molecules to airway epithelium | |
| CO2020010270A2 (es) | Vector recombinante para terapia génica de la distrofia muscular de cinturas tipo 2c | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| WO2021226267A3 (en) | Cross-species compatible adeno-associated virus compositions and methods of use thereof | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| WO2020093018A8 (en) | A codon optimized otoferlin aav dual vector gene therapy | |
| EP4631509A3 (en) | Recombinant adenoviruses and use thereof | |
| CL2022000292A1 (es) | Partículas virales para uso en el tratamiento de sinucleinopatías tales como enfermedad de parkinson mediante terapia genética | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| MX2021004688A (es) | Distrofinas miniaturizadas y usos de las mismas. | |
| EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор | |
| MX2019008105A (es) | Virus. | |
| ZA202304290B (en) | Nucleic acid constructs, viral vectors and viral particles | |
| EA202092069A1 (ru) | Композиции и способы лечения макулярной дистрофии | |
| MX2021002041A (es) | Terapia génica para el tratamiento de galactosemia. | |
| MX2020002148A (es) | Vectores adenoasociados recombinantes. | |
| PH12021550661A1 (en) | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy | |
| EP4223320A3 (en) | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) | |
| MX2024009890A (es) | Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas | |
| WO2020188228A8 (en) | Methods of optimising expression and delivery of mitochondrial proteins | |
| MX2025014958A (es) | Terapia genica para trastornos de la audicion | |
| EA202092654A1 (ru) | Генная терапия сердца с помощью aav при кардиомиопатии |